Instil Bio (TIL) announced the clearance of an Investigational New Drug application for AXN-2510 by the U.S. FDA. Instil expects to initiate a phase 1 trial of ‘2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. The trial is designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of ‘2510 in patients with solid tumors. Additionally, Instil continues to anticipate that initial safety and efficacy results from the ongoing phase 2 study of ‘2510 in combination with chemotherapy in first-line NSCLC in China will be shared in the second half of 2025 by ImmuneOnco.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL:
- Instil Bio adds Maraganore to the Board of Directors of Axion Bio
- Instil Bio Positioned as a Promising Player in the PD-1/L1 x VEGF Market with Strong Buy Recommendation
- Instil Bio appoints Jamie Freedman as CMO
- Instil Bio Elects Director and Ratifies Auditor
- Instil Bio Advances Phase 2 Trial in China